3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Meet Veristat at the TOPRA Symposium 2024, 30 September - 2 October, Rotterdam, the Netherlands, Booth 23
As TOPRA delegates navigate a changing healthcare world, Veristat plays an important role in helping them overcome regulatory complexities while bringing novel therapies to market.
Members of Veristat’s regulatory team—prominent leaders in regulatory affairs—are excited to exhibit, understand your needs, and highlight innovative opportunities to advance your therapy’s development.
Our extensive expertise in regulatory consultancy and clinical research across the product lifecycle is the perfect complement to TOPRA’s knowledge-building mission of providing world-class knowledge for all regulatory professionals.
Veristat Attendees
Anja Buhrer , Veristat Vice President, Regulatory Affairs
John Kirk , Veristat Regulatory Strategist
Delphine Guerin , Veristat, Business Development Director
Schedule A Meeting
Fill out the form to schedule a meeting with our Regulatory experts. Learn how Veristat can support you in driving your upcoming clinical trial or regulatory submission toward a successful outcome.
Conference Details
Website: TOPRA Symposium 2024
Schedule A Meeting
Meet with us at the TOPRA Symposium 2024 by filling out the form below.
Event Topics:
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...